NL-OMON38905撤回不适用
Safety, efficacy and immunogenicity of HPV 16 E7 DNA vaccination in HPV related squamous cell cancer. - DNA vaccination in squamous cell cancer.
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 35 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •HPV positive squamous cell cancer of the cervix, penis, vagina, vulva or head and neck region
- •No options for curative treatment (phase I)
- •HPV positive cancer of the cervix, of which at least 50% HPV16+ (phase II)
- •Eligible for chemoradiation (phase II)
- •Age above 18 years
- •Performance state WHO <=< 2
- •Life expectancy of 3 months or more
- •No indiciation of an active infectious disease
- •No history of autoimmun disease or systemetic undercurrent diease which might affect immunocompetence
- •Evaluable disease
- •Adequate bonemarrow, renal function and live function
- •Willing and able to undergo the planned study procedures
- •Last chemotherapy or radiotherapy more than 4 weeks ago (if applicable)
排除标准
- •Severe cardiac, respiratory or metabolic disease
- •Symptomatic brain metastases
- •Use of steroids or other immunosuppressive drugs
- •Use of oral anticoagulant drugs
- •Other cancers
- •Severe infections requiring antibiotics
- •Lactation of pregnancy (if applicable)
- •Not willing to take adequate contraceptive measures (if applicable)
研究者
相似试验
已完成
不适用
Testing the safety and immune response of HPV-DNA vaccination in patients with a HPV-positive preinvasive lesion of the vulva.VIN III lesion, immunotherapy, HPVVIN III laesie, immuuntherapie, HPVNL-OMON27857KI-AV12
已完成
不适用
Safety, toxicity and immunogenicity of HPV16 E7 DNA vaccination in HPV16+ vulvar intraepithelial neoplasia grade III: a phase I study.VINIIIvulvar dysplasia10038595NL-OMON40423Antoni van Leeuwenhoek Ziekenhuis12
已完成
4 期
Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant RecipientsLate Complication From Kidney TransplantComplication of Transplanted LiverHuman Papillomavirus-Related CarcinomaNCT02624349The Hospital for Sick Children37
撤回
2 期
Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection SystemVaccine ReactionNCT06142461PharmaJet, Inc.
已完成
3 期
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years OldInfections, PapillomavirusNCT01627561GlaxoSmithKline148